Lates News

American biopharmaceutical company Biohaven experienced a short-term plunge, with its overall intraday decline expanding to 21%. The company has withdrawn its experimental drug Troriluzole application in the European market. This drug has been studied as a potential treatment for Machado-Joseph disease, obsessive-compulsive disorder, and glioblastoma.